Corcept Therapeutics clinical trials we track

Check company identity source

Phase 3 4 trials

Phase 2 8 trials

TrialDrugs studiedStatusPrimary completion
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersNCT06906341Bevacizumab 10 mg/kg, Nab-paclitaxel 80 mg/m^2, Relacorilant 150 mg once daily (QD)Recruiting2027-12Estimated
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaNCT07259317Gemcitabine, Nab-paclitaxel, RelacorilantRecruiting2027-09Estimated
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeNCT03604198relacorilantActive not recruiting2026-12Estimated
Dazucorilant in Patients With Amyotrophic Lateral SclerosisNCT05407324Dazucorilant, Dazucorilant 150 mg, Dazucorilant 300 mgActive not recruiting2026-10Estimated
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)NCT06108219Miricorilant (Cohort A), Miricorilant (Cohort B)Completed2026-02-13Actual
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)NCT04524403MiricorlilantCompleted2022-07-29Actual
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsNCT03818256MiricorilantCompleted2022-06-17Actual
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT03776812Nab-paclitaxel, RelacorilantCompleted2021-03-16Actual

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2026. After: 13 Feb 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression-free Survival as Assessed by BICR Description: Time from randomization until the time of first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first Time frame: Up to 24 months from enrollment of the last patient Measure: Overall survival Description: Time from randomization to death by any cause Time frame: Up to 24 months from enrollment of the last patient. After: Measure: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Description: PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal progression in a non-target lesion, or the appearance of new lesions. Time frame: Up to 20 months Measure: Overall Survival Description: Overall survival (OS) was assessed as the time from randomization to death by any cause. The data values are Kaplan-Meier estimates. Time frame: Up to 32 months.

Primary completion date changed

Before: 24 Mar 2025. After: 31 Mar 2025.

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression-Free Survival (PFS). After: Measure: Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1) Measure: Number of Patients with 1 or More Adverse Events (AEs) Leading to Study Drug Discontinuations or Dose Modifications (Part 1) Measure: Progression-Free Survival (PFS) (Part 2).

Planned enrollment increased by 20 participants

Before: 60 participants (planned). After: 80 participants (planned).

Primary completion date changed

Before: Jul 2027. After: Sep 2027.

Check registry source

· 5 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score. Measure: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs.. After: Measure: Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score. Measure: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs Measure: Incidence of treatment-emergent AEs and SAEs Measure: Incidence of treatment-emergent AEs leading to dose interruptions, dose reductions, and/or discontinuations of study drug.

Participant count type changed

Before: Actual. After: Estimated.

Enrollment · participant count changed

Before: 249 participants (actual). After: 279 participants (planned).

Completion date type changed

Before: Actual. After: Estimated.

Primary completion date changed

Before: 22 Oct 2024. After: Sep 2026.

Check registry source